The mouse IGF-I gene contains six exons, and exon 1 and exon 2 gene are considered to be leader exons. The regulatory mechanism of alternative usage of the leader exons is unclear in mice. The present study was aimed at clarifying changes in class 1 (derived from exon 1) and class 2 (derived from exon 2) IGF-I mRNA expression in mice under various conditions. Both class 1 and class 2 IGF-I mRNAs were expressed in the mouse uterus, liver and kidney, and class 1 IGF-I mRNA was the major transcript in all organs studied. In the uterus, both class 1 and class 2 IGF-I mRNA expression changed markedly during the estrous cycle, with the highest level at proestrus, but in the liver and kidney there were no significant changes in IGF-I mRNA expression during the estrous cycle. Estrogen treatment increased both class 1 and class 2 IGF-I mRNA levels in the uterus of ovariectomized mice, but class 1 mRNA expression increased more in response to estrogen treatment than class 2 mRNA expression. These findings suggest that estrogen stimulates IGF-I gene expression in uterine cells, and that a promoter involved in transcription of class 1 IGF-I mRNA is more responsive to estrogen. In conclusion, the present study revealed that two leader exons of mouse IGF-I gene are used in the uterus, liver and kidney. IGF-I mRNA levels of both classes changed during the estrous cycle in the uterus, but not in the liver or kidney. Estrogen increased IGF-I mRNA levels of both classes in the uterus.
INTRODUCTION
Insulin-like growth factor-I (IGF-I) is an integral component of multiple systems controlling somatic growth, and regulates cell-cycle progression and apoptosis (LeRoith et al., 1995; Resnicoff et al., 1995; Jung et al., 1996; Parrizas and LeRoith, 1997) . IGF-I, a basic peptide of 70 amino acids is synthesized in precursor forms and processed post-translationally. The mammalian IGF-I gene consists of six exons (Rotwein et al., 1986; Shimatsu and Rotwein, 1987; Kamai et al., 1996) . Exons 1 and 2 are considered to be leader exons, and encode distinct 5'-flanking untranslated regions and signal peptide sequences. Alternative usage of the two leader exons results in the generation of two types of IGF-I transcripts (class 1 and class 2). Exon 1 is spliced to exon 3 to produce class 1 IGF-I mRNA, and exon 2 is spliced to exon 3 to produce class 2 IGF-I mRNA Adamo et al., 1989 Adamo et al., , 1991 Jansen et al., 1991) . Exon 3 encodes the remainder of the signal peptide and the first part of the B domain of the IGF-I peptide. Exon 4 encodes the remainder of the B, C, A and D domains, as well as the first part of the E peptide moiety of the prohormone. Exon 5 is an alternatively spliced cassette exon of 52 base pairs (bp).
In the human IGF-I gene two alternatively used promoters are located upstream of exon 1 and exon 2, respectively. Differential usage of the promoters has been observed both in vitro and in vivo (Jansen et al., 1992) . In the rat IGF-I gene two promoters are also found in the regions flanking exons 1 and 2 Hall et al., 1992) . In rats class 1 IGF-I mRNA derived from exon 1 is ubiquitous and predominant in all tissues studied, but class 2 IGF-I mRNA derived from exon 2 is found principally in the liver (Shemer et al., 1992) , and expression of class 2 IGF-I mRNA is more GH-sensitive than that of class 1 transcripts (Adamo et al., 1991) . These expression patterns suggest the organ-specific regulation of transcription.
In mice the presence of two promoters corresponding to the two leader exons (exons 1 and 2) has been suggested (Kamai et al., 1996) ; however, functional analysis of 5'-upstream flanking regions of the IGF-I gene has not been undertaken. In the present study the 3'-flanking regions of exons 1 and 2 of the mouse IGF-I gene were isolated and their sequences were determined to clarify the mouse IGF-I gene structure. The present study aimed to clarify the differential usage of two leader exons of the mouse IGF-I gene in the uterus. The uterus shows the next-highest level of IGF-I gene expression after the liver in rats and mice (Murphy et al., 1987) . IGF-I and the type I receptor for IGF-I (IGF-IR) are expressed in the mouse uterus (Kapur et al., 1992; Henemyre and Markoff, 1999; Ohtsuki et al., 2005) .
We investigated the steady-state levels of class 1 and 2 IGF-I mRNA expression in the uterus at different ages and different stages of the estrous cycle to clarify the alternative usage of the leader exons. Furthermore, the effects of estradiol-17β (E2) on class 1 and class 2 IGF-I mRNA expression in the uterus of ovariectomized mice was also studied, since estrogen stimulates IGF-I mRNA expression in the uterus (Murphy et al., 1987; Kapur et al., 1992; Inoue et al., 2005; Murakami et al., 2005; Ohtsuki et al., 2005) .
MATERIALS AND METHODS

Animals
Male and female ICR mice (CLEA Japan Inc., Osaka, Japan) were used in the present study. They were kept in a temperaturecontrolled animal room with free access to CE-7 commercial diet (CLEA Japan) and tap water ad libitum. Vaginal-smear sampling was conducted daily for at least two weeks. All animal care and experiments were performed in accordance with the Guidelines for Animal Experimentation of Okayama University, Japan.
RNA preparation and reverse transcription
Total RNA was extracted using the method of Chomczynski and Sacchi (1987) . Total RNA (2 μg) in a final volume of 20 μl was subjected to reverse transcription (RT) reaction using the Superscript Preamplification System for First Strand cDNA (Gibco BRL, Gaithersburg, MD, USA) with an oligo-dT primer, according to the manufacturer's instructions.
Isolation and sequence determination of the 3' flanking regions of mouse IGF-I exons 1 and 2
Mouse class 1 and class 2 IGF-I cDNA fragments obtained from the liver were amplified by RT-PCR with a forward primer specific for each leader exon (exon 1, 5'-ATGGGGAAAATCAGCAGTC-3'; exon 2, 5'-CTGCCTGTGTAAACGACCCGG-3') and a reverse primer (exon 3-4 junction, 5'-GGCTGCTTTTGTAGGCTTCAGTGG-3'). Mouse class 1-and class 2-specific primers were designed from data in previous reports on mouse exons 1 and 2 (Kamai et al., 1996) and mouse IGF-I cDNA (Bell et al., 1986) . PCR was performed using Takara Taq (Takara, Otsu, Japan) and a Gene Amp PCR System 9700 thermal cycler (Applied Biosystems, Branchburg, NJ). PCR products were electrophoresed on agarose gels. After ethidium bromide staining, class 1 (353 bp) and class 2 (333 bp) IGF-I cDNA fragments were excised from the gel and cloned into pGEM3Zf (+) (Promega, Madison, WI, USA), and sequenced with a BigDye Terminator Cycle Sequencing Kit v. 3.1 (Applied Biosystems, Foster City, CA, USA) using the appropriate PCR primers.
Semi-quantitative analysis of the number of copies of class 1 and class 2 IGF-I cDNAs Class 1 and class 2 IGF-I cDNA fragments were amplified by PCR with the leader exon-specific primer sets for exon 1 (forward, class 1; reverse, exon 3-4 junction) and exon 2 (forward, class 2; reverse, exon 3-4 junction), and the PCR products were then electrophoresed on agarose gels. After ethidium bromide staining, class 1 (353 bp) and class 2 (333 bp) IGF-I cDNA fragments were excised from the gel and cloned into pGEM3Zf (+) (Promega). EcoRI-HindIII digested fragments were electrophoresed on agarose gels, and the fragments were isolated and then quantified by measurement of the optical density at 260 nm. The copy number of each cDNA was calculated using the following equation (Overbergh et al., 1999) copies per reaction), and the RT products of uteri and liver, were amplified by 26 PCR cycles of 20 sec at 95°C, 30 sec at 55°C, and 40 sec at 72°C, with an additional extension for 10 min at 72°C. PCR products were electrophoresed on agarose gels. After ethidium bromide staining, the band intensity was quantified by Kodak 1D image software (Version 3.6). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA, amplified using a specific primer set (Ohtsuki et al., 2005) , was used as an internal control.
Semi-quantitative RT-PCR analysis of class 1 and class 2 IGF-I mRNA levels Class 1 and class 2 IGF-I mRNA fragments were semi-quantified by RT-PCR with the leader exon-specific primer sets described above. PCR conditions were as follows: initial activation of DNA polymerase by a 20-sec incubation at 90°C; 30 cycles of 1 min at 95°C, 1 min at 55°C, and 2 min at 72°C; and an additional extension for 10 min at 60°C. Ten-μl aliquots of PCR product of each reaction were electrophoresed on 2% agarose gel, stained with ethidium bromide, and quantified. Class 1 and class 2 IGF-I mRNA expression levels were normalized with H2A.X mRNA levels (Ohtsuki et al., 2005) . In a preliminary study we had confirmed that the PCR products of both class 1 and class 2 IGF-I mRNA increased linearly from 22 to 26 cycles (liver), from 24 to 28 cycles (uterus) and from 26 to 28 cycles (kidney).
Ovariectomy and estrogen treatment
Adult female mice were ovariectomized at 8 weeks of age under light ether anesthesia. Seven days later, they were subcutaneously injected with estradiol-17β (E2, Sigma-Aldrich, St. Louis, MO, USA; E2 was dissolved in sesame oil) at doses of 25 and 250 ng/mouse (0.1 ml) or with the same volume of sesame oil. At 0, 3, 6, 12, 24, 48, 72 and 96 hr after E2 treatment, uteri were collected for RNA extraction.
Statistics
Data are presented as the mean±standard error of the mean (SEM) and were analyzed by analysis of variance with the post-hoc Bonferroni/Dunn test.
RESULTS
Comparison of nucleotide sequences of the 3'-flanking regions of exons 1 and 2 of the mouse and rat IGF-I genes
The DNA sequences of mouse and rat IGF-1 exons 1 and 2 are aligned in Fig. 1A and 1B. Exon 1 and exon 2 showed high degree of identity between the mouse and rat IGF-I genes. The 3'-flanking region of mouse IGF-I exon 1 analyzed shared 100% identity with that of rat IGF-I exon 1. The 3'-flanking region of mouse IGF-I exon 2 analyzed shared 91.4% identity with that of rat IGF-I exon 2.
Expression profiles of class 1 and class 2 IGF-I mRNA in the uterus and liver
Using a known number of copies of class 1 and class 2 IGF-I cDNA as templates in PCR, class 1 (derived from exon 1) and class 2 (derived from exon 2) IGF-I mRNA levels were analyzed in adult female mice. The PCR products of each class of IGF-I cDNA increased in accordance with the increase of template cDNAs under the PCR conditions used ( Fig. 2A) . Class 1 and class 2 IGF-I mRNAs were detected in the uterus (U) and liver (L) by RT-PCR (Fig. 2B) . Both class 1 and class 2 IGF-I mRNA levels were higher in the liver than in the uterus. The amount of class 1 PCR products generated from the uterine and liver samples was more than the amount of PCR products generated from the class 1 templates (1.0×10 6 copies), and the amount of class 2 PCR products generated from the uterine and liver samples was less than the PCR products generated from the class 2 templates (5.0×10 5 copies). The numbers of copies of class 1 and class 2 IGF-I cDNAs were determined: in the uterus, class 1 had 1.8×10 6 copies and class 2 had 3.2×10 5 copies; in the liver, class 1 had 3.6×10 6 copies and class 2 had 3.8×10 5 copies.
Changes in class 1 and class 2 IGF-I mRNA levels during the estrous cycle To determine changes in class 1 and class 2 IGF-I expression during the estrous cycle in the uterus, liver and kidney, class 1 and class 2 IGF-I mRNA levels were measured in 60-day-old female mice by RT-PCR analysis (Fig. 3) . Class 1 and class 2 IGF-I mRNA levels on the first day of diestrus (D1) were defined as 1. In the uterus, class 1 and class 2 IGF-I mRNA levels changed markedly during the estrous cycle. The highest levels of both types of IGF-I mRNA were detected at proestrus. No significant changes in class 1 and class 2 IGF-I mRNA levels were detected in the liver and kidney during the estrous cycle. 
Fig. 2. RT-PCR analysis of IGF-I mRNA variant expression in the mouse uterus (U) and liver (L) using exon 1-and exon 2-specific primer pairs (see Materials and Methods
copies per reaction) IGF-I were amplified by 26 PCR cycles (see Materials and Methods). (B)
Comparison of class 1 and class 2 IGF-I mRNA expression in the uterus (U) and liver (L) by RT-PCR. Samples from the uterus and liver and cDNA samples (class 1, 1.0×10 6 copies; class 2, 5.0×10 5 copies) were amplified by PCR under the same conditions as for (A). GAPDH cDNA was used as an internal control. A 100-bp ladder was used as a molecular size marker (M). The number to the left depicts the size of products (bp).
Effect of E2 on class 1 and class 2 IGF-I mRNA expression in the uterus of ovariectomized mice
The time course of the effect of E2 on uterine class 1 and class 2 IGF-I mRNA levels was studied by RT-PCR analysis (Fig. 4) . E2 treatment (25 and 250 ng) increased class 1 IGF-I mRNA levels markedly from 6 hr to 12 hr after E2 injection (Fig. 4A) ; in contrast, class 2 IGF-I mRNA levels changed at 6 hr (Fig. 4B) . The highest levels of class 1 IGF-I mRNA were detected at 6 hr irrespective of the dose used. At 6 hr, 13-fold and 20-fold increases in class 1 IGF-I mRNA levels were detected with E2 treatment at 25 and 250 ng, respectively, while a fourfold increase in class 2 IGF-I Fig. 3 . Changes in class 1 and class 2 IGF-I mRNA expression in the uterus (A), liver (B), and kidney (C) during the estrous cycle. RNA samples were collected at proestrus (P), estrus (E), the first day of diestrus (D1), and the second day of diestrus (D2), and class 1 and class 2 IGF-I mRNA levels were determined by RT-PCR analysis, as described in Materials and Methods. Class 1 IGF-I mRNA levels are expressed by open bars, and class 2 by closed bars. Each mRNA level was normalized relative to the H2A.X mRNA level. The mRNA levels at D1 were defined as 1. Data are expressed as the mean±SEM (n=5). * P<0.05, significantly different from the level at D1. Fig. 4 . Effect of E2 on class 1 (A) and class 2 (B) IGF-I mRNA expression in the uteri of ovariectomized mice. Ovariectomized mice were given a single injection of E2 (25 or 250 ng/mouse) or the vehicle, which was sesame oil. Class 1 and class 2 IGF-I mRNA levels were determined by RT-PCR analysis, as described in Materials and Methods. IGF-I mRNA levels were normalized relative to the H2A.X mRNA level. The mRNA level at 0 hr was defined as 1. Data are expressed as the mean±SEM (n=3). * P<0.05, ** P<0.01, significantly different from the vehicle-treated control; # P<0.05, ## P<0.01, significantly different from the level at 25 ng E2-treated. mRNA levels was detected with E2 treatment at 250 ng.
DISCUSSION
Mouse IGF-I mRNAs are classified based on the usage of leader exons 1 and 2. Class 1 IGF-I mRNA is transcribed from exon 1, and class 2 from exon 2. Expression of the two leader exons of the mouse IGF-I gene was detected in the uterus, liver and kidney, as reported for human and rat IGF-I genes Adamo et al., 1989; Shemer et al., 1992) . We semi-quantitatively analyzed IGF-I mRNA expression and found that class 1 IGF-I mRNA was the major transcript type and showed higher expression than class 2; this is in agreement with previous reports Adamo et al., 1989 Adamo et al., , 1991 . The presence of multiple leader exons and differences in IGF-I mRNA levels transcribed suggest the presence of distinct promoters controlling IGF-I gene transcription, which have already been reported for human and rat IGF-I genes Jansen et al., 1992; Wang et al., 1997) . The physiological significance of the presence of multiple leader exons, and probably multiple promoters, resulting in the production of multiple types of transcripts of the IGF-I gene is unclear. However, the presence of multiple promoters for IGF-I gene transcription appears to be favorable for the organ-specific and fine control of IGF-I synthesis under various conditions, since IGF-I proteins are expressed in various cell types and have unique roles in the cells expressing them.
Two promoters of the mouse IGF-I gene are thought to be located in the 5'-flanking regions proximal to exons 1 and 2, but these two putative promoters have not yet been characterized (Kamai et al., 1996) . Usage of the leader exons was analyzed in mouse uterus, liver and kidney during the estrous cycle. In the uterus, class 1 and class 2 IGF-I mRNA expression changed markedly during the estrous cycle, with the highest levels at proestrus. There was a fivefold increase in class 1 expression and a fourfold increase in class 2 IGF-I mRNA expression in proestrus compared to the first day of diestrus, while in the liver and kidney there were no significant changes in class 1 or class 2 IGF-I mRNA expression during the estrous cycle.
Estrogen is well known to stimulate IGF-I gene expression in the uterus (Murphy et al., 1987; Kapur et al., 1992; Inoue et al., 2005; Murakami et al., 2005) , and we also showed the stimulatory role of estrogen in the expression of both types of IGF-I mRNAs in the mouse uterus. These findings indicate that the regulation of uterine class 1 and class 2 IGF-I mRNA expression is estrous cycle-dependent, and it is highly probable that the main regulator is estrogen, since blood estrogen levels are high during proestrus (Smith et al., 1975) . In contrast, we did not detect changes in IGF-I mRNA levels in the liver or kidney during the estrous cycle. In addition, hepatic IGF-I expression is not stimulated by estrogen treatment (Murphy and Friesen, 1988) . The difference in patterns of IGF-I mRNA expression during the estrous cycle between the uterus and the other organs is not due to differences in estrogen receptor expression, since estrogen receptor mRNA was detected in the uterus, liver and kidney by RT-PCR in mice (Ohtsuki et al., 2005; Manabe et al., unpublished observation) . The organ-specific regulatory mechanism of IGF-I gene expression, particularly under estrogen stimulation, needs to be studied.
Estrogen treatment increased both class 1 and class 2 IGF-I mRNA levels in the uterus of ovariectomized mice, which is in agreement with previous studies carried out in the rat uterus (Carlsson and Billig, 1991; Klotz et al., 2000) , but class 1 IGF-I mRNA expression increased more in response to estrogen treatment than class 2 expression. These findings indicate that estrogen activates two putative promoters of the IGF-I gene in uterine cells, and that a promoter involved in transcription of class 1 IGF-I mRNA is more responsive to estrogen. However, during the estrous cycle, both class 1 and class 2 IGF-I mRNA levels in the uterus changed in a similar manner. IGF-I gene transcription is regulated by multiple factors, and among them progesterone is one of the main regulators and enhances estrogeninduced IGF-I mRNA expression (Kapur et al., 1992) . Changes in IGF-I mRNA levels in the uterus during the estrous cycle may be regulated by not only estrogen, but also progesterone. It is highly probable that combined effects of estrogen and progesterone enhance the promoter activity involved in class 2 IGF-I mRNA expression in the uterus.
In chickens, the IGF-I gene is stimulated by estrogen through the AP-1 motif located in the promoter region (Umayahara et al., 1994) . In rats, CCAAT enhancer-binding protein δ (C/EBPδ) is a critical regulator of IGF-I gene transcription (Umayahara et al., 1999) , and estrogen decreases IGF-I gene expression in osteoblasts through the cAMP pathway with C/EBPδ (Chang et al., 2005) . However, the mechanism of estrogen-induced IGF-I gene expression in the uterus remains unclear, and further study concerning the regulatory mechanism of uterine IGF-I gene expression is needed.
IGF-I is expressed in the endometrial luminal and glandular epithelia, stroma and myometrium in rats and mice (Murphy et al., 1987; Ghahary et al., 1990; Kapur et al., 1992) . Enhanced IGF-I mRNA expression of both classes in the uterus at proestrus and estrus leads to the production of IGF-I protein. IGF-I stimulates DNA synthesis and the proliferation of uterine epithelial cells in rats and mice (Beck and Garner, 1992; Shiraga et al., 1997) . Proliferation of uterine epithelial cells induced by estrogen is mediated by polypeptide growth factors synthesized in uterine tissues (Cooke et al., 1997) . These findings suggest that IGF-I is a candidate as an estrogen-induced growth factor that regulates the proliferation of endometrial epithelial cells. Adesanya et al. (1999) demonstrated that IGF-I is involved in the G2 progression of mouse uterine cells under estrogen stimulation, although IGF-I is generally considered to act in the G1 phase as a G1-progression factor (Pestell et al., 1999) .
We recently found alternative splicing of IGF-I mRNA in mice, generating two variants of IGF-I mRNA, IGF-IA and IGF-IB (Ohtsuki et al., 2005) . Both IGF-IA and IGF-IB mRNAs are generated from each of class 1 and class 2 IGF-I mRNA, resulting in the production of four variants of IGF-I mRNAs. Both IGF-IA and IGF-IB mRNA levels in ovariectomized mouse uteri were elevated by E2 treatment, which is in agreement with a previous rat uterus study (Klotz et al., 2000) . The relative increase in class 1 IGF-I mRNA levels with estrogen was higher than that in class 2 levels. Therefore, estrogen may stimulate the alternative usage and splicing that generates class 1 IGF-I mRNA variants. Interest-ingly, an exonic splicing enhancer is located in human alternative exon 5 of the IGF-I gene, and serine-arginine protein splicing factor-2/alternative splicing factor promotes the splicing of human IGF-I mRNA (Smith et al., 2002) . If a similar system operates in the mouse uterus, estrogen may be involved in the activation of the alternative splicing-factor system.
In conclusion, the present study revealed that two leader exons of mouse IGF-I gene operate in the uterus, liver and kidney, and that there are probably two promoters for IGF-I gene expression. Estrous cycle-dependent IGF-I gene expression was found in the uterus alone. Estrogen increased uterine IGF-I mRNA levels of both classes. The usage of the leader exons of the mouse IGF-I gene was controlled in an organ-specific and hormone (estrogen)-dependent manner.
